14th Annual Summit on the Medicaid Drug Rebate Program

For fourteen years, IIR’s MDRP event has been at the forefront of policy changes and operational compliance. This year, President Obama’s budget proposals contain provisions that will directly impact Medicaid Rebate processes.

Can you afford to wait and see how sweeping reform will impact your business?

The MDRP summit provides a strategic action plan that will position your organization to weather increased oversight of the OIG and respond to sweeping regulatory reform, as well as the other pricing related legislative proposals that have the potential to impact your job.

Change has come to Washington and there is no doubt there will be changes to both Medicaid and Medicare which will directly impact Medicaid Drug Rebates. Join us in September, for a keynote presentation from a key architect in the congressional reform proposals, Senator Tom Daschle, as he shares his of how the proposed changes on Capitol Hill will impact the pharmaceutical industry and Medicaid Drug Rebates.

Visit our website www.medicaiddrugrebates.com for what else is new at the 2009 MDRP.

We look forward to greeting you again in Chicago this September!

Share this article with your social network, just click below to share now!

Share |

Exclusivity period for biologics

Obama believes that biologics should be able to face competition after seven years on the market instead of 12-14.

Nancy-Ann DeParle, director of the Office of Health Reform, and Peter Orszag, director of the Office of Management and Budget wrote a letter to Rep. Henry Waxman stating

"Lengthy periods of exclusivity will harm patients by diminishing innovation and unnecessarily delaying access to affordable drugs."

Read the full article here.

If you're interested in networking with other professionals in the field of Biosimilars, join our LinkedIn Group here.

Share this article with your social network, just click below to share now!

Share |

Waxman pushes for biosimilars approvals now

Congressman Henry Waxman thinks President Obama should begin approving biosimlars before the bill passes. In his bill, he believes that biosimilars should have an exclusive five year exclusivity for biologics.

In a letter to the president, he wrote, "I urge the administration to consider what steps can be taken under existing authority to prepare and even begin to use a pathway for generic biologics."

Read the full story here.

If you're interested in networking with other professionals in the field of Biosimilars, join our LinkedIn Group here.

Share this article with your social network, just click below to share now!

Share |

Biosimilars Bill Offers New Hope

This post on Pharmafocus discusses that the US has gotten a step closer to being able to market generic verions of biologic drugs in the USA for the first time, if the Pathway for Biosimilars Act is passed. Europe has seen a similar legislation pass in 2003, but now the Obama administration seems determined to bring biosimilars here in the US to reduce on healthcare costs. There is much skepticism though as many people say that biosimilars do not behave the same way as originator drugs when it comes to safety and efficacy. What is your take?

If you’re interested in connecting with other professionals in the Biosimilars field, join us at LinkedIn.

Share this article with your social network, just click below to share now!

Share |

Sam's Club Packages Electronic Medical Records Software

This article in Reuters discusses how Wal-mart's Sam's Club stores will begin selling packages including software and Dell computers directly to doctors for electronic medical records. Susan Koehler, a Sam Club spokeswoman, mentions that they are trying to help smaller practice doctors with the software and hardware needed to access medical records at an affordable cost.

Wal-mart already offers walk-in medical clinics, and this according to Susan is part of how they got the idea of offering electronic health packages. The package, which includes help with training, installation, and maintenance will cost the first doctor in a practice roughly $25,000 with each additional user costing around $10,000.

This all comes at a time when President Barack Obama is pushing electronic medical records as a way to cut healthcare costs, increase efficiency, and reduce errors. IBM already offers such software, it will be interesting to see the companies that will soon follow suit.

Share this article with your social network, just click below to share now!

Share |